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Pituitary adenylate cyclase-activating polypeptide (PACAP), which is found in 27- or 38-
amino acid forms, belongs to theVIP/glucagon/secretin family. PACAP and its three receptor
subtypes are expressed in neural tissues, with PACAP known to exert a protective effect
against several types of neural damage. The retina is considered to be part of the central
nervous system, and retinopathy is a common cause of profound and intractable loss of
vision.This review will examine the expression and morphological distribution of PACAP and
its receptors in the retina, and will summarize the current state of knowledge regarding
the protective effect of PACAP against different kinds of retinal damage, such as that
identiﬁed in association with diabetes, ultraviolet light, hypoxia, optic nerve transection,
and toxins. This article will also address PACAP-mediated protective pathways involving
retinal glial cells.
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INTRODUCTION
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a
neuropeptide which was originally isolated from ovine hypotha-
lamus on the basis of its capacity to stimulate adenylate cyclase
activity in pituitary cells (Miyata et al., 1989). PACAP exists in
two forms containing 27 and 38 amino acid residues, respec-
tively, with PACAP27 sharing 68% sequence homology with that
of vasoactive intestinal polypeptide (VIP). PACAP belongs to the
VIP/secretin/glucagon family of peptides (Arimura and Shioda,
1995). PACAP38 is the predominantly expressed form in mam-
mals (Arimura et al., 1991). The amino acid sequence of PACAP
has been well conserved in vertebrates, implying that PACAP
may act as an important neuropeptide (Sherwood et al., 2000).
The receptors for PACAP, of which there are three main types,
belong to the G protein-coupled receptor family with seven trans-
membrane domains. The PAC1 receptor (PAC1R) binds PACAP
with high afﬁnity and VIP with a much lower afﬁnity, while the
VPAC1 and VPAC2 receptors (VPAC1R, VPAC2R) bind VIP and
PACAP with similar afﬁnities (Harmar et al., 2012). PACAP is a
pleiotropic biological peptide which regulates vasodilation, acti-
vates intestinal motility, increases insulin and histamine secretion,
and modulates immune responses in peripheral tissues (Vaudry
et al., 2009). In the central nervous system (CNS), PACAP acts
as a neurotransmitter, neuromodulator, and/or neurotrophic fac-
tor (Arimura, 1998; Nakamachi et al., 2011). One of the most
important functions of PACAP is that of neuroprotection. In
this way, PACAP suppresses neuronal damage against acute brain
injuries such as brain ischemia, traumatic brain injury, and spinal
cord injury (Farkas et al., 2004; Ohtaki et al., 2008; Tsuchikawa
et al., 2012). Moreover, PACAP protects the brain against neu-
rodegenerative disease (Reglodi et al., 2011), reducing the level
of neuronal damage. The retina is considered as a specialized
neuronal tissue containing different types of neurons and glial
cells. Therefore, to reveal any functions of PACAP in this tis-
sue, it is necessary to understand which cell types in the retina
express PACAP and PACAP receptors. The purpose of this review
is to provide an overview of the distribution of PACAP and
its receptors in the retina, and to summarize current knowl-
edge of the protective functions of PACAP in animal models of
retinopathy.
EXPRESSION OF PACAP AND ITS RECEPTORS
IN RETINAL TISSUE
PACAP DISTRIBUTION
From a morphological perspective, light microscopy immuno-
histochemistry studies have shown PACAP-like immunoreactivity
(-LI) exists in a population of sensory neurons in the rat uvea
(Moller et al., 1993; Mulder et al., 1994) and in rabbit trigemi-
nal ganglion cells (Onali and Olianas, 1994). Nerve ﬁbers with
PACAP-LI have also been found in the uvea of the rat eye
(Moller et al., 1993; Mulder et al., 1994). PACAP-LI in the eye
was studied by radio-immunoassay and the highest concentra-
tions were found in the iris sphincter and ciliary body (Onali
and Olianas, 1994; Wang et al., 1995). Furthermore, immuno-
histochemical studies revealed that PACAP-positive nerve ﬁbers
were present in the nerve ﬁber layer (NFL), the ganglion cell
layer (GCL), and the inner plexiform layer (IPL). PACAP-positive
neuronal cell bodies were also found in amacrine and hori-
zontal cells in the inner nuclear layer (INL). No PACAP-LI
was found in photoreceptors in the outer nuclear layer (ONL)
or retinal pigmented epithelium (Seki et al., 1997, 1998; Izumi
et al., 2000).
At the ultrastructural level, PACAP-LI was found in some
amacrine and horizontal cells in the INL. PACAP-LI was detected
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in the plasma membrane and rough endoplasmic reticulum,
and diffusible immunoreactive products were detected in the
cytoplasmic matrix of amacrine cells and horizontal cells. Intense
PACAP-LI was detected in cell processes of the IPL,GCL, and NFL.
In the IPL, PACAP-positive amacrine cell processes make synap-
tic contacts with retinal ganglion cell (RGC) terminals, as well
as amacrine and bipolar cell processes. PACAP-positive amacrine
cell processes have also been identiﬁed to make synaptic contacts
with each other. In the IPL, PACAP-positive presynaptic axon
terminals were found to contain several dense granular vesicles
(80–100 nm in diameter) and many small clear synaptic vesi-
cles (30–50 nm in diameter). However, precise ultrastructural
localization of PACAP-LI in the axon terminals is very difﬁcult
to determine with the pre-embedding immunostaining method.
Electron microscopy observations of the IPL revealed non-speciﬁc
immunoreactive products associated with post-synaptic mem-
branes, the outer mitochondrial membrane, and the cytoplasmic
matrix of axon terminals (Seki et al., 2000b). PACAP-LI is also
expressed in the cell bodies of some amacrine and horizon-
tal cells in the INL and their processes in the IPL, GCL, and
NFL in the rat retina, as shown by both light and electron
microscopic immunocytochemistry. PACAP-positive axon termi-
nals make synaptic contact with RGC, bipolar cells, amacrine
cells, and horizontal cells in the GCL, NFL, and IPL. On the
other hand, VIP-positive cells have also been found in the GCL
and INL, and their ﬁbers have been found in the IPL (Loren
et al., 1980). Both PACAP- and VIP-positive cells and ﬁbers are
found in the rat retina but their distributions are quite differ-
ent from each other. These studies strongly suggest that PACAP
and VIP function as neurotransmitters and/or neuromodula-
tors, but the functions of PACAP may be different from those
of VIP.
PACAP RECEPTOR DISTRIBUTION
Receptor binding sites for PACAP and VIP, positively coupled to
adenylate cyclase, have been previously described in the retina
of different mammalian species (D’Agata and Cavallaro, 1998).
As to the localization of PAC1R in the rat retina (Nilsson et al.,
1994), we have described the distribution and localization of
PAC1R and its mRNA in the rat retina by immunohistochem-
istry and in situ hybridization histochemistry (Seki et al., 1997,
2000a). PAC1R-LI was found in the cell bodies and processes of
RGC and amacrine cells. No PAC1R-LI was observed in photore-
ceptors. At the ultrastructural level, PAC1R-LI was detected in the
plasma membrane, rough endoplasmic reticulum, and the cyto-
plasmic matrix of RGCs and amacrine cells in the INL. There
are certain areas in which the localization of PACAP does not
match that of PAC1R. For example, in the rat brain, PAC1R
has been found at very high levels in the olfactory bulb, hip-
pocampus, and cerebellar cortex, where few PACAP-containing
neurons are identiﬁed (Seki et al., 1997). Reports also suggest that
PACAP is a transmitter and/or modulator which regulates RGCs
and amacrine cells in the rat retina. Müller cells were difﬁcult to
identify in histological observations, but PAC1R-LI was observed
in rat primary cultures of Müller cells (Seki et al., 2006a). PACAP
and PAC1R distributions in the rodent retina are summarized in
Figure 1.
PACAP AND NEUROPROTECTION
Protective effect of PACAP on retina and retinal cells against vari-
ous types of retinopathy animal models and toxic reagent showing
below was summarized in Table 1.
PACAP AND DIABETES (DIABETIC RETINOPATHY)
It is well known that diabetes causes numerous health com-
plications in the human body, with one of the most serious
consequences of this disease being diabetic retinopathy. The rea-
son for the retinal degeneration is that the retina is unable to adapt
to the metabolic changes caused by hyperglycemia. This situation
leads to chronic inﬂammation and microvascular angiopathy (Liu
et al., 2008). One of the most important consequences of dia-
betes is the changes to enzyme activities and altered expression
patterns of growth and transcription factors (Seki et al., 2004).
Another reason for the degeneration of the retina is related to
oxidative stress (Kowluru and Abbas, 2003). Increased produc-
tion of reactive oxygen species (ROS) may play an important
role in the development of diabetic complications as it has been
shown that ROS levels are elevated in the diabetic rat retina
and in retinal cells incubated in high glucose media (Kowluru
and Abbas, 2003; Cui et al., 2006) due to the hyperglycemia-
induced impairment of antioxidant defense systems (Kowluru
et al., 1996). The progression of diabetic retinopathy is slow, and
leads to a decrease in a number of cell types in the retina such
as amacrine cells, RGCs, and both types of photoreceptors (rod
and cone cells; Holopigian et al., 1997; Gastinger et al., 2006).
Müller cells and retinal astrocytes are also affected, becoming reac-
tive within 3 months of the onset of diabetes (Lieth et al., 1998).
Increased glial ﬁbrillary acidic protein (GFAP) expression has been
reported, particularly in the early phase of the disease (Lieth et al.,
1998), which is closely associated with the activation of Müller
cells.
Some studies have shown that PACAP treatment could protect
the retina against theharmful effects of diabetes. In streptozotocin-
treated rats, PACAP (100 pmol in 5 μl saline) administered into
the vitreous body three times over the course of a week was able
to attenuate the decrease of the cell number in the GCL (Szabadﬁ
et al., 2012b). The PACAP treatment was also effective with respect
to Müller cells in that the streptozotocin injection increased GFAP
immunoreactivity in the retina due to Müller cell activation, but
thePACAP treatmentwas able to signiﬁcantly decrease the number
of GFAP-positive Müller cells compared with untreated animals
(Szabadﬁ et al., 2012b).
The PACAP treatment also increased the expression pattern of
PAC1R in the diabetic retina, particularly in tyrosine-hydroxylase
(TH)-positive cells (Szabadﬁ et al., 2012b). The most important
TH-positive cells in the retina are the amacrine cells. The mor-
phological or functional degeneration of dopaminergic amacrine
cells was observed during the early stage of STZ-induced diabetes
(Seki et al., 2004), and it was recently conﬁrmed immunohisto-
chemically that intravitreally injected PACAP is able to protect
the amacrine cells from such degeneration (Atlasz et al., 2010b).
Diabetes also causes changes in the expression of several apop-
totic factors. Three weeks after streptozotocin injection, B-cell
lymphoma 2 (Bcl-2) expression was decreased and p53 expression
was increased, both of which indicate an elevated level of apoptosis
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FIGURE 1 | Schematic diagram of PACAP and PAC1R distributions in the rodent retina. Black color indicates PACAP or PAC1R-expressing cells according
to previous reports.
of the retinal cells. The intravitreal injection of PACAP (100 μmol
in 5 μl of saline) was able to block these changes and restore the
Bcl-2 and p53 levels to near control (Giunta et al., 2012). These
results suggest that PACAP is able to up-regulate anti-apoptotic
pathways and down-regulate pro-apoptotic pathways.
PACAP AND ULTRAVIOLET-A LIGHT-INDUCED RETINOPATHY
Only one paper has been published concerning the capacity of
PACAP to protect against ultraviolet (UV) light-induced retinopa-
thy. Exposure of animals for 45 min to diffuse UV-A irradiation
caused cell death especially in the ONL and INL of the retina, and
the thickness of the retina decreased in line with the duration of
the UV-A treatment. One day after the UV-A treatment the GCL
was not affected, but following a second day after illumination a
signiﬁcant decrease of the number of RGCs was observed. The
intravitreal administration of PACAP (100 pmol in 5 μl saline)
immediately after the irradiation was able to protect the ONL and
INL of the retina which are seriously affected by the UV-A light,
and thenumberof the cells in INL,ONL,andGCLwas signiﬁcantly
increased as a consequence of the PACAP treatment (Atlasz et al.,
2011). This effect of PACAP may have been via a reduction in the
level and toxicity of free radicals generated as a consequence of the
exposure to the UV-A. PACAP may thus reduce UV-A radiation-
induced retinal damage and edema in a manner similar to that
in which it reduces ischemia-induced cerebral damage and edema
(Ohtaki et al., 2008; Nakamachi et al., 2010).
PACAP AND HYPOXIA
The retina has an elevated oxygen uptake compared to other tis-
sues,making it one of the most sensitive tissues in the human body
to hypoxia. Several diseases can cause retinal ischemia, the most
common of which are cardiovascular disorders such as carotid
artery stenosis, retinal artery occlusion, diabetic retinopathy, or
high intraocular pressure, which can compress the blood vessels
of the retina and cause hypoperfusion (Seki et al., 2011). An opti-
mal way to model retinal ischemia in rats is the bilateral common
carotid artery occlusion (BCCAO) technique; however the out-
come of the operation may depend on the rat strain and technique
used (Block et al., 1992; Szabadﬁ et al., 2010). The permanent
ligation of both common carotid arteries leads to a reduction
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in the cerebral blood ﬂow in rats (Farkas et al., 2005; Lavinsky
et al., 2006), which can cause severe retinal damage. All layers
of the retina can be affected, with the reduction of the blood
ﬂow usually leading to a decrease of the thickness of the retina,
especially with respect to the inner and outer plexiform layers
(Atlasz et al., 2007; Atlasz et al., 2010b). The photoreceptors can
also be damaged, with their outer segments becoming shorter,
and alterations to their structure appearing after the BCCAO
(Atlasz et al., 2010b).
In recent years, several studies have been published concern-
ing retinoprotective strategies and agents developed to combat
retinal ischemia. Because decreased perfusion leads to a range of
changes in the retina, such as an altered metabolism of glutamate,
increased levels of ROS, mitochondrial failure, and activation
of inﬂammatory mediators, several possibilities to reduce the
harmful effects of ischemia have been proposed (Szabadﬁ et al.,
2010). For example, numerous retinoprotective agents or meth-
ods have been tested in the last few years against the harmful
effects of retinal ischemia; these include VIP, poly ADP-ribose
polymerase (PARP) inhibitors, brain-derived neurotrophic fac-
tor (BDNF), antioxidants, ﬂavonoids, pre- or post-conditioning,
etc. (Atlasz et al., 2010a; Szabadﬁ et al., 2010). Both in vitro and
in vivo studies have shown PACAP to be one of the best candi-
dates to protect retinal cells and to reduce the effects of ischemia.
In an early report, turtle retina fragments were maintained in
non-oxygenated Ringer solution for 46 h, with added PACAP38
(0.165 μM) able to protect the horizontal cells against ischemia;
after 42 and 46 h, the light response of the cells was signiﬁcantly
higher than responses obtained from control group fragments
(Rabl et al., 2002).
Several papers were published thereafter concerning the retino-
protective action of PACAP against the effects of hypoxia. PACAP
possibly acts via PAC1R, which is detectable in all layers of the
retina and is strongly expressed in the GCL, INL, NFL, and more
weakly in the IPL,OPL, and ONL (Seki et al., 1997, 2000a). PACAP
(10 pmol in 5 μl saline) intravitreally administered immediately
after the BCCAO operation signiﬁcantly reduced the harmful
effects of ischemia compared to sham-operated animals. This
protective effect was signiﬁcantly attenuated by the PACAP38
antagonist, PACAP6-38 (Atlasz et al., 2007). Several cell types in
the retina can be damaged by ischemia. A decrease of vesicular
glutamate transporter 1 (VGLUT1) transporters causes damage to
photoreceptors, bipolar cells, and calcium binding proteins, giving
rise to the degeneration of different types of neurons. Moreover,
increased GFAP expression is a sign of Müller cell and astrocyte
activation. These effects were attenuated by PACAP treatment
after the BCCAO (Atlasz et al., 2010b), suggesting that PACAP
has a general cytoprotective effect in the retina against hypoxic
conditions.
This effect of PACAP38 was conﬁrmed in another study
on wild-type and PACAP-null CD1 mice exposed to tran-
sient (10 min) BCCAO. Directly after the operation PACAP38
(100 pmol in 3 μl saline) was administered into the vitreous body.
The results of the operation and treatment were tested 2 weeks
later. The 10-min BCCAO resulted in a thinner retina, with signif-
icantly greater damage evident in the PACAP-null animals. In this
group all the retinal layers were affected, while in the wild-type
animal abnormalities were only evident in the INL. Intravitreal
PACAP38 treatment signiﬁcantly attenuated the deleterious effects
of BCCAO in both groups. These results suggest that the retina
in PACAP-null animals is more sensitive to ischemia compared
to that in wild-type mice, and that PACAP treatment is effective
against retinal ischemia inbothwild-type andPACAP-null animals
(Szabadﬁ et al., 2012a).
Another technique to transiently decrease retinal blood ﬂow is
to artiﬁcially elicit intraocular hypertension. This is a glaucoma
model, where a thin needle is inserted into the anterior chamber
of the eye of adult rats and 0.9% saline is injected to temporarily
increase the intraocular pressure up to 100 mmHg for 60 min. The
result of this procedure is similar to that achieved with BCCAO,
in that under these experimental conditions the intraocular pres-
sure is greater than the blood pressure in the vessels of the retina,
thereby causing a hypoxic state in the retina. This treatment leads
to a decrease in the number of RGCs and in the thickness of
the retina, especially the IPL (Seki et al., 2011). PACAP38 treat-
ment was also effective in combating this situation given that,
compared with untreated eyeballs; the number of the RGCs was
higher in animals treated with PACAP38. The effect of the PACAP
was signiﬁcantly stronger compared to the vehicle-treated animals
when 3 μl of PACAP38 solution at concentrations of 10 fM, 10
or 100 pM was administered. This result suggests that the PACAP
has a bimodal effect with peaks at 10 fM and 10–100 pM, even
though the mechanism accounting for these effects was not the
same. In the case of the 10 fMPACAPadministration, themitogen-
activated protein kinase (MAPK) inhibitor PD-98059 signiﬁcantly
reduced the protective effect of PACAP, but there was no sig-
niﬁcant difference observed at the other PACAP concentrations
tested. Meanwhile, the cAMP antagonist Rp-cAMP signiﬁcantly
decreased the effect of PACAP at all the concentrations tested
(Seki et al., 2011). These results suggest that pathways involving
MAPK and cAMP play key roles in the protective effect of PACAP
against hypoxia. A recent study revealed additional information
concerning this phenomenon. Adult rat retinas were examined
5, 30, and 60 min after BCCAO accompanied by injections of
100 nmol/3 μl of PACAP. The results showed that in the absence
of any harmful stimulus, the PACAP did not cause any changes
compared with the control group. Ischemia itself caused several
changes, such as increases in the phosphorylation of Akt, ERK 1/2,
JNK, or p38MAPK, particularly at the 30 and 60 min time points
following the operation. PACAP treatment caused a signiﬁcant
increase in the phosphorylation of Akt and ERK 1/2 at all time
points, and decreased the activity of JNK and p38MAPK (Szabo
et al., 2012). Several results were published previously concern-
ing the effect of PACAP on these signal transduction pathways in
the retina and other tissues (Dohi et al., 2002; Ohtaki et al., 2006;
Racz et al., 2006; Shioda et al., 2006). PACAP has important, but
variable, effects on the expression of interleukins and cytokines.
The expression of several interleukins such as inter interleukin
(IL)-1, intercellular adhesion molecule (ICAM), L-selectin, reg-
ulated and normal T cell expressed and secreted (RANTES) etc,
was decreased by PACAP, while levels of others such as IL-2, IL-6,
IL-10, and tumor necrosis factor (TNF)-α were not changed. In
contrast, the levels of vascular endothelial growth factor (VEGF)
and thymus chemokine were increased (Szabo et al., 2012).
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Not only ischemia, but also hyperoxia cause oxidative stress
which could be harmful for cells in the retina. Oxidative stress
is one of the most important apoptosis-inducing factors in the
human body, especially in the CNS and sensory organs (Vaudry
et al., 2002; Racz et al., 2010). Retinal pigment epithelial cells are
sensitive to oxidative stress, with hydrogen peroxide- or aldehyde-
induced oxidative stress leading to apoptosis of these cells in vitro
(Kalariya et al., 2008; Kook et al., 2008). Given that retinal pigment
epithelial cells express PAC1R and VPAC receptors (Zhang et al.,
2005), PACAP could have a cytoprotective effect on these cells.
When retinal pigment epithelial cells were treated with 0.25 mM
H2O2 and 10 nM PACAP38 for 3 h, the survival of these cells was
signiﬁcantly ameliorated compared with control cells not treated
with PACAP. An MAPK inhibitor in this case had no inﬂuence on
the effect of PACAP38, but inhibition of the phosphoinositide 3-
kinase (PI3K)/Akt pathway and PACAP6-38 treatment were able
to antagonize this cytoprotective effect (Mester et al., 2011). The
p38MAPK, c-Jun N-terminal kinase (JNK), extracellular signal-
regulated kinase (ERK) 1/2, and Akt pathways were also activated
in response toH2O2 treatment, while PACAP38 decreased the level
of p38MAPK and pJNK, and increased the activity of the ERK 1/2
and Akt pathways. Other cytokine and signal transduction path-
ways are modiﬁed by H2O2 and PACAP38 treatment. Oxidative
stress induced the expression of several apoptosis-inducing fac-
tors such as Bad, Bax, Trail, Fas-associated protein with death
domain (FADD), Fas, second mitochondrial-derived activator
of caspase (SMAC), and several heat-shock proteins (HSP32,
HMOX2, and HSP27), as well as p53. Co-treatment with both 100
and 10 nM PACAP38 decreased the activation all of these factors
(Fabian et al., 2012).
PACAP AND OPTIC NERVE TRANSECTION
Optic nerve injury caused by trauma, glaucoma, or neurodegen-
erative disease can cause apoptotic RGCs death (Quigley et al.,
1995), for which, based on the above ﬁndings, PACAP could be a
good candidate to protect injured RGCs against apoptosis. In one
recent study, different concentrations of PACAP38 were adminis-
tered into the vitreous body of adult rats, and immediately after
the injection, the optic nerve was transected (Seki et al., 2008).
Fourteen days later the number of the RGCs was found to be sig-
niﬁcantly decreased in the control (untreated) and PACAP-treated
groups due to apoptosis. The PACAP38 treated groups, however,
showed increased RGC survival compared with control, particu-
larly with regard to the groups receiving injections of 3 μl of saline
containing 10 and 100 pM PACAP.
PACAP AND TOXINS
Many toxic agents have been identiﬁed which can cause severe
retinal injury. Some of them, like glutamate, are found in the reti-
nal cells and are necessary in small concentrations for the normal
functioning of the retina. Others, like anisomycin and thapsigar-
gin, are not endogenous to the retina and are commonly used in in
vivo studies to induce retinal injury by direct administration into
the vitreous body.
Anisomycin
The capacity of PACAP to prevent the deleterious effects of
this drug was examined on in vitro preparations of the retinal
neuroblastic layer from newborn rats. This drug inhibits protein
synthesis and causes cell death in the neuroblastic layer. It was
previously found that increased cAMP levels protect retinal cells
against retinal damage induced by protein synthesis inhibition
(Rehen et al., 1996). In this way, 1 nM PACAP38 or PACAP27
administered in parallel with anisomycin had a protective effect
on the neuroblastic layer (Silveira et al., 2002). PACAP38 exerts
its action via the PAC1 receptor, which is expressed in all layers
of the neonatal retina, and activates the cAMP/protein kinase A
(PKA) pathway, which is essential for this effect. The activation
of other PAC1R-activated signal transduction pathways, such as
the phospholipase C (PLC) or PI3K pathways, is not necessary for
the protective effect of PACAP against anisomycin (Silveira et al.,
2002). On the other hand, PACAP6-38 and Maxadilan (a speciﬁc
PAC1R antagonist) inhibit this neuroprotective effect of PACAP38
(Silveira et al., 2002).
Thapsigargin
Thapsigargin is a non-competitive inhibitor of the endoplasmic
reticulum Ca2+-ATPase. This drug inhibits autophagia, which
leads to cell death. In the case of retinal explants of newborn
rats, thapsigargin causes apoptosis of the photoreceptors in the
ONL (Chiarini et al., 2000). PACAP38 treatment was also effec-
tive against thapsigargin-induced damage, with 1 nM PACAP38
administered simultaneously with 10 nM thapsigargin effectively
preventing damage to the photoreceptors of the ONL (Silveira
et al., 2002).
Kainic acid
Kainic acid is a glutamate receptor agonist which is able to cause
dose-dependent excitotoxicity-related injury to the retina. The
intraocular injection of a low dose (6–20 nmol/retina) of this drug
causes damage to the amacrine cells, with a 60 nmol/retina dose
sufﬁcient to cause degeneration of the bipolar and horizontal cells.
Higher doses of kainic acid lead to the disappearance of the inner
and outer plexiform layers in the chicken retina, while the pho-
toreceptors and RGCs survived the treatment across the range
of doses employed (Morgan and Ingham, 1981). The intravitreal
administration of this drug in rats causes excitotoxic injury and
cell death in the retina, especially in the INL, IPL, andCGL. PACAP
(10 pmol) administered into the vitreous body 2 days before the
kainic acid treatment resulted in a signiﬁcantly lower incidence of
cell death in the mentioned layers; however the co-administration
of PACAP and kainic acid did not provide any protective effect in
the retina (Seki et al., 2006b).
N-methyl-D-aspartate
N-methyl-D-aspartate (NMDA) is a selective glutamate receptor
agonist, which is able to mimic the effect of glutamate. It is how-
ever speciﬁc to its NMDA receptor only, and it has no effect on
other glutamate receptors such as the AMPA or kainite receptors.
NMDA treatment induces an excitatory effect on several cell types
in the CNS (Parsons et al., 1998; Watkins and Jane, 2006). In the
retina, NMDA receptors are expressed by RGCs and amacrine
cells (Fletcher et al., 2000), with the overstimulation of NMDA
receptors causing retinal excitotoxicity which leads to neuronal
cell death in the retina (Sucher et al., 1991), particularly in the
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GCL. NMDA is a drug commonly used to artiﬁcially create nor-
motensive glaucoma models, and for testing anti-glaucoma drugs
(Yamashita et al., 2011). PACAP could be a good candidate to com-
bat NMDA-induced retinal injury because it is able to reduce the
harmful effects associatedwith the intravitreal injectionof NMDA.
The effect of NMDA treatment was more severe in PACAP-null
mice than in wild-type animals, with the decrease in the number
of RGCs signiﬁcantly greater on the ﬁrst, third, and seventh days
after the injection of 40 nmol NMDA in 2 μl saline (Endo et al.,
2011). In this way, endogenous PACAP production can be seen
to play an important role in the protection of retinal cells against
NMDA-induced damage (Endo et al., 2011). PACAP38 co-injected
with NMDA signiﬁcantly increased the survival of RGCs both in
wild-type and PACAP-null animals. The most effective concentra-
tion of PACAP38 in the case of treatment of the retina of wild-type
mice was 100 pM (Endo et al., 2011).
Monosodium glutamate
Under normal conditions, the amino acid derivate glutamate is
one of the most important excitatory neurotransmitters in the
CNS. This molecule and its receptors are also present in the
retina where they have an essential function. However, gluta-
mate also plays a key role in neurological and retinal diseases,
as well as in pathological conditions of the eye (Sucher et al., 1991;
Danysz and Parsons, 2002). Monosodium glutamate (MSG) is
one of the most commonly used drugs to induce retinal injury
in different animal models or in vitro studies. In recent years,
many papers have been published concerning MSG-induced reti-
nal cytotoxicity, and treatments that are able to protect retinal cells
against the harmful effects of increased glutamate levels. Several
studies suggest that drugs such as glutamate receptor blockers,
hormones, neuropeptides, or pre- and post-conditioning could
be effective in treating pathological conditions where the gluta-
mate level is increased (Lombardi and Moroni, 1994; Russo et al.,
2008; Fernandez et al., 2009). PACAP could also be an interesting
candidate for this given that it has been shown to be retino-
protective in several retinal degeneration models, as mentioned
above, and is known to exert a protective effect against glutamate
toxicity.
Newborn rat retinal cell primary cultures were exposed for
10 min to 1 mM glutamate which caused a signiﬁcant decrease
in their viability (Shoge et al., 1999). Treatment of the cells with
either PACAP38 or PACAP27 was protective in a dose-dependent
manner (1 nM to 1 μM) against this glutamate-induced damage,
with a maximum protective effect observed at a concentration of
100 nM. After a 10-min treatment with PACAP, the level of PKA
and the MAPK activity of the cells were elevated. PACAP6-38 and
H-89 (a selective PKA inhibitor) were able to attenuate the positive
effects of PACAP27 and PACAP38.
In addition to these in vitro results, some in vivo studies have
suggested that PACAP is effective against glutamate toxicity. The
intravitreal treatment with MSG of newborn rats causes severe
degeneration in many layers of the retina. The average thickness
of the retina was decreased, the IPL almost disappeared, and the
INL and CGL layers seemed to fuse with each other (Tamas et al.,
2004; Babai et al., 2005; Atlasz et al., 2009). Simultaneously admin-
istered PACAP38 and PACAP27 (100 pmol in 5 μl saline) were
able to signiﬁcantly attenuate the MSG-induced damage to the
retina. Although the retina was thinner than that in untreated con-
trols, damage to the affected layers of the retina was not so severe
(Tamas et al., 2004; Babai et al., 2006; Atlasz et al., 2007). How-
ever, if more than one MSG injection was given into the vitreous
body, one PACAP treatment was not enough to provide protection
against the repetitive excitotoxic stimuli. The PACAP treatment
was successful only in the case where PACAP (100 pmol) was
administered at least two times in parallel with the MSG injection
(Babai et al., 2005).
An important question concerns the combined and additive
effects of different treatments against the excitotoxic effect of the
glutamate. An interesting study published in 2010 addressed the
effect of enriched environments to combat the effects of MSG.
MSG was injected into the vitreous body of newborn rat pups
and it was found that animals maintained in a bigger cage with
colorful objects exhibited reduced glutamate damage compared
with controls maintained under standard conditions. A similar
or enhanced result was seen in cases where pups maintained
under standard conditions were treated with PACAP (100 pmol
diluted in 5 μl saline). However, the protective effect of the
enriched environment and PACAP co-injection was not additive
(Kiss et al., 2011).
Most studies published in the last few years examined the
cytoprotective effect of PACAP from a morphological perspec-
tive, but no information is usually given about improvements
in retinal function following the treatment of glutamate-induced
damage. Until now, only one paper has been published in
which the functional effects of MSG and PACAP treatments
were measured by electroretinogram (ERG). Newborn rats were
treated with MSG (2 mg/g bodyweight) administered subcuta-
neously on the ﬁrst, ﬁfth, and ninth days postnatal. PACAP
(100 pmol diluted in 5 μl saline) was administered into the
vitreous body in half of the pups on the same days. The ERG
examination was performed 2 months later, with results showing
that the subcutaneous MSG injection attenuated the ERG wave
amplitude, and that PACAP treatment was able to signiﬁcantly
improve the functional performance of the damaged retina (Varga
et al., 2011).
DIRECT AND INDIRECT PATHWAYS
Pituitary adenylate cyclase-activating polypeptide suppresses neu-
ronal activity in the CNS via direct and indirect pathways (Shioda
et al., 2006). The direct pathway infers that PACAP affects target
neurons expressing the PACAP receptor. As shown above, PAC1R
was detected in GCLs and amacrine cells in the retina (Figure 1),
suggesting that PACAP affects these kinds of neurons directly. On
the other hand, PACAP is also expressed by RGCs and amacrine
cells (Figure 1). It is known that endogenous PACAP has neuro-
protective functions in the CNS (Ohtaki et al., 2006; Nakamachi
et al., 2010; Reglodi et al., 2012). Indeed, PACAP knockout mouse
deteriorate retinal damage in some retinopathy animal models
(Endo et al., 2011; Szabadﬁ et al., 2012a), which implies that
endogenousPACAPprotects retinal neurons via auto- or paracrine
mechanisms. Signaling pathways involving the protective function
of PACAP on neurons have been elegantly summarized by Atlasz
et al. (2010a).
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In the case of indirect pathways, PACAP is known to stimulate
the secretion of neuroprotective factors in the CNS (Somogyvari-
Vigh and Reglodi, 2004), although little is known about PACAP’s
indirect mode of action in the retina. IL-6 is recognized as a
proinﬂammatory cytokine, but it acts as a neuroprotectant in
the CNS (Loddick et al., 1998; Moidunny et al., 2010), and has
been considered as a possible player in PACAP’s indirect neuro-
protective pathway. PACAP administration signiﬁcantly increases
IL-6 mRNA and protein expression levels in the murine brain,
with neurons and astrocytes identiﬁed as the source of PACAP-
induced IL-6 secretion (Tatsuno et al., 1996; Ohtaki et al., 2006;
Nakamachi et al., 2012). In the mouse brain, PACAP-induced neu-
roprotection is absent in the IL-6 knockout mouse, suggesting
that PACAP suppresses neuronal damage via an IL-6-mediated
pathway (Ohtaki et al., 2006). PACAP also has the potential to
stimulate IL-6 secretion in the retina. The addition of PACAP to
primary cultures of rat Müller cells signiﬁcantly augmented IL-6
levels in the culture medium in a manner that was inhibited by
PACAP6-38 treatment (Nakatani et al., 2006; Seki et al., 2006a).
Indeed, PAC1R protein was detected in rat primary cultures of
Müller cells (Kubrusly et al., 2005). These data suggest that IL-6
released from Müller cells may mediate PACAP-induced retinal
protection. Recent reports suggest that Müller cells secrete many
types of neurotrophic factors, growth factors, and cytokines, such
as BDNF and neurotrophin-3, glial cell-line derived neurotrophic
factor (GDNF), neurturin, ciliary neurotrophic factor (CNTF),
endothelin-2, leukemia inhibitory factor (LIF), basic ﬁbroblast
growth factor (bFGF), and prostaglandin E2 (Bringmann et al.,
2009). These factors may be related to the neuroprotective effect
of PACAP as well as IL-6. Furthermore, microglial cells exist in
the retina, and inﬁltrating macrophages were identiﬁed in the
retina after injury (Chen et al., 2002; Davies et al., 2006). This
microglia/macrophage system has been considered as a regulator
of immunity and inﬂammation after retinal damage (Wraith and
Nicholson,2012). Further study focusing on retinal glial cells in the
mechanism of PACAP neuroprotection will provide new insights
of the protective network involving PACAP.
CONCLUSION AND FUTURE PERSPECTIVES
In the clinical setting, retinal neuropathies are a major cause of
visual impairment that are yet to have a deﬁnitive cure. Alterna-
tive therapeutic strategies for addressing optic neuropathies are
therefore required. Neurotrophic factors such as BDNF, ciliary
neurotrophic factor, and glial cell line-derived neurotrophic factor
have been shown to ameliorate RGC damage in an animal model
of retinopathy (Johnson et al., 2011). However, the actions of these
growth factors have not yet been well elucidated to enable them
to be considered as target candidates of neuroprotective drugs
to treat retinal neuropathies. In this review, we have shown that
PACAP consistently exerts a potent protective effect against neu-
ral damage in a broad range of retinal diseases. As future studies
involving PACAP will likely shift to obtaining a fuller understand-
ing of the mechanisms underlying such protective functions, an
important aspect of this will be to examine pathways involving
glial cells. These insights will help in the development of new
neuroprotective strategies to treat retinal neuropathies.
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